Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Safety and Error PreventionMedicationIssue 724

Emergency Recall of the OTC Weight-loss Drug Alli

Several reports of tampering have been made nationwide.... 

Advertisement

Multiple reports of tampered Alli products have been reported throughout the United States, prompting an emergency recall of this OTC weight-loss drug.

Reports of tampered bottles containing different types of pills, in various shapes and colors, first began to pour in on Wednesday from consumers in Alabama, Florida, Louisiana, Mississippi, New York, North Carolina and Texas. Many of these bottles were missing labels, packed in a sealed box, and had tamper-evident seals that did not appear genuine.

The manufacturer, GlaxoSmithKline, is currently working with the U.S. Food and Drug Administration in their investigation. The stage in the supply chain where the productions were tampered with still remains unknown.

Product tampering is a serious crime in America and finding the source of this is essential. According to a spokeswoman for GlaxoSmithKline, "The investigation is ongoing... We've asked people to return bottles to us, so we can examine them very closely ... we don't have any theories at this point."

The contents found within the tampered Alli products are currently unknown. As of now, at least 20 inquiries have been made. No reports of harm have been reported.

Practice Pearls:
  • Alli is an OTC weight-loss supplement currently approved for obesity in adults in conjunction with a healthy diet
  • Weight-loss supplements are popular throughout the U.S. and many patients may be using them
  • Anyone who has purchased Alli® and believes it has been tampered with should contact the FDA and manufacture immediately

Hirschler B, Goodman D. GSK recalls weight-loss drug Alli in U.S. on tampering concerns. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 10 April, 2014 and appeared in  Safety and Error PreventionMedicationIssue 724

Past five issues: Diabetes Clinical Mastery Series Issue 216 | Issue 756 | Diabetes Clinical Mastery Series Issue 215 | SGLT-2 Inhibitors Special Edition November 2014 | Issue 755 |

2014 Most Popular Articles:

New SGLT2 Inhibitor Likely To Be Approved for Type 2 Diabetes
Posted November 14, 2014
Grapefruit Juice May Affect Insulin Resistance
Posted October 23, 2014
New Approach Targets Type 2's Poorly Controlled With Metformin
Posted November 14, 2014
Very Low Carbohydrate, Low Saturated Fat Diet for Type 2 Diabetes Management
Posted November 07, 2014
Dietary Magnesium Intake's Role in Decreasing Metabolic Syndrome
Posted October 31, 2014
FDA Accepts Filing of NDA for Empagliflozin/Metformin Fixed-dose Combination
Posted October 23, 2014
Handbook of Diabetes, 4th Ed., Excerpt #16: Diabetic Neuropathy
Posted November 02, 2014
What's Hiding in that Insulin Box?
Posted October 27, 2014
Exercise Promotes Preservation of Beta Cells
Posted November 14, 2014
Interview with NuSirt CEO Joe Cook, Jr: Improving Metformin Treatment, Part 1
Posted November 02, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
If the U.S. Affordable Care Act is reversed in the new congress, what impact will that have on your patients?


Advertisement


Search Articles On Diabetes In Control